Cao Zhijie, Kon Ning, Liu Yajing, Xu Wenbin, Wen Jia, Yao Han, Zhang Mi, Wu Zhen, Yan Xiaojun, Zhu Wei-Guo, Gu Wei, Wang Donglai
State Key Laboratory of Medical Molecular Biology and Department of Medical Genetics, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China.
Institute for Cancer Genetics, Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Sci Adv. 2021 Mar 31;7(14). doi: 10.1126/sciadv.abf4148. Print 2021 Mar.
Cancer cell-intrinsic programmed cell death protein-1 (PD-1) has emerged as a tumor regulator in an immunity-independent manner, but its precise role in modulating tumor behaviors is complex, and how PD-1 is regulated in cancer cells is largely unknown. Here, we identified PD-1 as a direct target of tumor suppressor p53. Notably, p53 acetylation at K120/164 played a critical role in p53-mediated PD-1 transcription. Acetylated p53 preferentially recruited acetyltransferase cofactors onto PD-1 promoter, selectively facilitating PD-1 transcription by enhancing local chromatin acetylation. Reexpression of PD-1 in cancer cells inhibited tumor growth, whereas depletion of cancer cell-intrinsic PD-1 compromised p53-dependent tumor suppression. Moreover, histone deacetylase inhibitor (HDACi) activated PD-1 in an acetylated p53-dependent manner, supporting a synergistic effect by HDACi and p53 on tumor suppression via stimulating cancer cell-intrinsic PD-1. Our study reveals a mechanism for activating cancer cell-intrinsic PD-1 and indicates that p53-mediated PD-1 activation is critically involved in tumor suppression in an immunity-independent manner.
癌细胞内在的程序性细胞死亡蛋白1(PD-1)已以一种不依赖免疫的方式成为肿瘤调节因子,但其在调节肿瘤行为中的精确作用很复杂,并且PD-1在癌细胞中如何被调控在很大程度上尚不清楚。在此,我们确定PD-1是肿瘤抑制因子p53的直接靶点。值得注意的是,p53在K120/164位点的乙酰化在p53介导的PD-1转录中起关键作用。乙酰化的p53优先将乙酰转移酶辅因子招募到PD-1启动子上,通过增强局部染色质乙酰化选择性地促进PD-1转录。在癌细胞中重新表达PD-1可抑制肿瘤生长,而去除癌细胞内在的PD-1则会损害p53依赖的肿瘤抑制作用。此外,组蛋白去乙酰化酶抑制剂(HDACi)以乙酰化p53依赖的方式激活PD-1,支持HDACi和p53通过刺激癌细胞内在的PD-1对肿瘤抑制产生协同作用。我们的研究揭示了激活癌细胞内在PD-1的机制,并表明p53介导的PD-1激活以不依赖免疫的方式关键地参与肿瘤抑制。